Experimental combo aims to tackle Hard-to-Treat prostate cancer

NCT ID NCT07250542

Recruiting now Disease control Sponsor: baotai Liang Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of fasudil hydrochloride and an immunotherapy drug (tirapibep) in 30 men with metastatic castration-resistant prostate cancer that has progressed after standard treatments. Participants receive the drugs alongside standard hormone therapy over four 21-day cycles. The study aims to see if the combination is safe and can lower PSA levels, a marker of cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fasudil hydrochloride combined with PD-1 monoclonal antibody (tirapibep)
What this could lead to: If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The treatment may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Zhongda Hospital
RECRUITING

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.